Please assess the completion status of the following clinical trial:

Trial Title: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, locally advanced, not amenable to curative therapy, or metastatic NSCLC~* ALK-rearrangement confirmed by the Food and Drug Administration (FDA) approved test~* NSCLC that has failed crizotinib treatment~* Measurable disease as defined by RECIST v1.1~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\<=) 2~* Adequate hematologic, hepatic and renal function~Exclusion Criteria:~* Prior therapy with ALK inhibitor other than crizotinib~* Brain or leptomeningeal metastases that are symptomatic and/or requiring treatment~* History of serious cardiac dysfunction~* History of or current active infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)~* Clinically significant gastrointestinal abnormality that would affect absorption of the drug~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alectinib: Phase I (Dose Escalation) (Type: EXPERIMENTAL): Participants will receive escalating doses of alectinib capsules orally until disease progression, death or withdrawal for any other reasons.
- Alectinib (Phase II: RP2 dose) (Type: EXPERIMENTAL): Participants will receive recommended Phase II dose as determined from Phase I until disease progression, death or withdrawal for any other reasons.

Based on this trial design, predict the completion outcome and termination type (if applicable).